DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Urelumab is an investigational drug.
There have been 7 clinical trials for Urelumab. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Non-Hodgkin, Neoplasms, and Lymphoma, B-Cell. The leading clinical trial sponsors are Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, and M.D. Anderson Cancer Center.
There are twelve US patents protecting this investigational drug and one hundred and eighty international patents.
Recent Clinical Trials for Urelumab
|Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors||Clinica Universidad de Navarra, Universidad de Navarra||Phase 1/Phase 2|
|Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer||Bristol-Myers Squibb||Phase 1|
|Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer||University of Chicago||Phase 1|
Top disease conditions for Urelumab
Top clinical trial sponsors for Urelumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Urelumab||See Pricing||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||See Pricing|
|Urelumab||See Pricing||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||See Pricing|
|Urelumab||See Pricing||Constructs having a SIRP-.alpha. domain or variant thereof||ALX ONCOLOGY INC. (Burlingame, CA)||See Pricing|
|Urelumab||See Pricing||Methods and compositions for treating conditions associated with an abnormal inflammatory responses||First Wave Bio, Inc. (Ann Arbor, MI)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|